BioCentury
ARTICLE | Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

January 25, 2020 12:15 AM UTC
Updated on Jan 25, 2020 at 1:17 AM UTC

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least one other biosimilar as well as an innovator product. Even with the discounts, however, two of the three biosimilars’ list prices will be about double the original biologics’ launch prices.

On Thursday, the pharma launched Ruxience rituximab-pvvr, its biosimilar of Rituxan rituximab from Genentech Inc. and Biogen Inc. (NASDAQ:BIIB), at a discount of 24%. While it will compete with Truxima rituximab-abbs from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) as a therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia, Pfizer said it is the first FDA-approved biosimilar to treat granulomatosis with polyangiitis and microscopic polyangiitis, for which Rituxan is also approved...

BCIQ Company Profiles

Pfizer Inc.